Hyloris Pharmaceuticals

Hyloris Pharmaceuticals company information, Employees & Contact Information

We are a specialty biopharma company focused on innovating, reinventing, and optimising existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors. We have built a broad proprietary pipeline of complex value-added reformulated and repurposed products that have the potential to offer significant advantages over currently available medications. Today, we have two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a novel, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain. Our development strategy of reformulating and repurposing approved pharmaceuticals primarily utilises the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for which the safety and efficacy have already been established. This focused strategy can dramatically reduce the clinical burden required to bring a product to market, and significantly shortens the development timelines while also reducing costs and risks. Hyloris is based in Liège, Belgium. For more information, visit www.hyloris.com.

Company Details

Employees
44
Founded
-
Address
Boulevard Patience Et Beaujonc, N°3/1,belgium
Phone
+32 (0)4 346 02 07
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
|….
HQ
Liège, Walloon Region
Looking for a particular Hyloris Pharmaceuticals employee's phone or email?

Hyloris Pharmaceuticals Questions

News

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties - PR Newswire

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties PR Newswire

Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in Canada - Yahoo Finance

Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in Canada Yahoo Finance

Hyloris announces U.S. FDA Approval of Maxigesic® IV - GlobeNewswire

Hyloris announces U.S. FDA Approval of Maxigesic® IV GlobeNewswire

Hyloris Pharma wins US FDA approval for pain treatment - Reuters

Hyloris Pharma wins US FDA approval for pain treatment Reuters

Hyloris Pharmaceuticals : Inside Information Hyloris Announces Partnership with Grand Life Sciences Group for HY-094 in China ENGLISH VERSION - MarketScreener

Hyloris Pharmaceuticals : Inside Information Hyloris Announces Partnership with Grand Life Sciences Group for HY-094 in China ENGLISH VERSION MarketScreener

Hyloris Pharmaceuticals SA's (EBR:HYL) Path To Profitability - simplywall.st

Hyloris Pharmaceuticals SA's (EBR:HYL) Path To Profitability simplywall.st

Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada - Yahoo Finance

Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada Yahoo Finance

Hyloris Pharmaceuticals Announces Move to LégiaPark Complex - GlobeNewswire

Hyloris Pharmaceuticals Announces Move to LégiaPark Complex GlobeNewswire

Hyloris partners with Huons to introduce dental products in South Korea - BioSpectrum Asia

Hyloris partners with Huons to introduce dental products in South Korea BioSpectrum Asia

Kye Pharmaceuticals partners with Hyloris Pharmaceuticals for the Development and Commercialization of Atomoxetine Oral Solution in Canada - PR Newswire Canada

Kye Pharmaceuticals partners with Hyloris Pharmaceuticals for the Development and Commercialization of Atomoxetine Oral Solution in Canada PR Newswire Canada

Hyloris announces enrolment of first patient in a 4-arm clinical trial of Alenura(TM) - Yahoo Finance

Hyloris announces enrolment of first patient in a 4-arm clinical trial of Alenura(TM) Yahoo Finance

After Leaping 27% Hyloris Pharmaceuticals SA (EBR:HYL) Shares Are Not Flying Under The Radar - simplywall.st

After Leaping 27% Hyloris Pharmaceuticals SA (EBR:HYL) Shares Are Not Flying Under The Radar simplywall.st

Hyloris announces submission of Maxigesic® IV packaging data requested by the US FDA - GlobeNewswire

Hyloris announces submission of Maxigesic® IV packaging data requested by the US FDA GlobeNewswire

Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group - GlobeNewswire

Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group GlobeNewswire

Hyloris Announces Further Extension of Maxigesic® IV Footprint - GlobeNewswire

Hyloris Announces Further Extension of Maxigesic® IV Footprint GlobeNewswire

Hyloris Acquires Breakthrough, Patented Technology to - GlobeNewswire

Hyloris Acquires Breakthrough, Patented Technology to GlobeNewswire

Top Hyloris Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant